☆ 4.4 Letter

Perforin gene variant A91V in young patients with severe COVID-19

HAEMATOLOGICA (2020)

Journal

HAEMATOLOGICA

Volume 105, Issue 12, Pages 2844-2846

Publisher

FERRATA STORTI FOUNDATION

DOI: 10.3324/haematol.2020.260307

Keywords

-

Categories

Hematology

Funding

FIS-Instituto de Salud Carlos III [COV20/00181, 20/167]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas, N. Brau, M. Waters, R. C. Go, B. D. Hunter, S. Bhagani, D. Skiest, M. S. Aziz, N. Cooper, I. S. Douglas, S. Savic, T. Youngstein, L. Del Sorbo, A. Cubillo Gracian, D. J. De la Zerda, A. Ustianowski, M. Bao, S. Dimonaco, E. Graham, B. Matharu, H. Spotswood, L. Tsai, A. Malhotra

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Immunology

TIGIT Monoallelic Nonsense Variant in Patient with Severe COVID-19 Infection, Thailand

Pimpayao Sodsai, Chupong Ittiwut, Vichaya Ruenjaiman, Rungnapa Ittiwut, Watsamon Jantarabenjakul, Kanya Suphapeetiporn, Vorasuk Shotelersuk, Nattiya Hirankarn

Summary: A heterozygous nonsense variant in the TIGIT gene was found in a patient with severe COVID-19 in Thailand, leading to lower TIGIT expression in T cells. The patient's T cells produced higher levels of cytokines upon stimulation. This mutation causes less-controlled immune responses, which might contribute to the severity of COVID-19.

EMERGING INFECTIOUS DISEASES (2022)

Add to Collection

Article Immunology

Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19

Luca Valenti, Samantha Griffini, Giuseppe Lamorte, Elena Grovetti, Sara Colonia Uceda Renteria, Francesco Malvestiti, Luigia Scudeller, Alessandra Bandera, Flora Peyvandi, Daniele Prati, Pierluigi Meroni, Massimo Cugno

Summary: This study found an association between genetic variation at chromosome 3p21.31 and ABO blood group with complement activation in COVID-19 patients, providing insights into the pathogenesis of severe COVID-19.

JOURNAL OF AUTOIMMUNITY (2021)

Add to Collection

Article Medical Laboratory Technology

Lipid metabolism changes in patients with severe COVID-19

Yi Li, Yan Zhang, Rongli Lu, Minhui Dai, Minxue Shen, Jianchu Zhang, Yanhui Cui, Ben Liu, Fengyu Lin, Lingli Chen, Duoduo Han, Yifei Fan, Yanjun Zeng, Wen Li, Sha Li, Xiang Chen, Haitao Li, Pinhua Pan

Summary: This study found that in severe COVID-19 patients, survivors showed an increasing trend in LDL-C, TC, HDL-C, and apoA-I, while non-survivors showed a decreasing trend. The concentrations of HDL-C and apoA-I were inversely correlated with CRP, length of hospital stay of survivors, and disease severity scores. High CRP/HDL-C ratio was significantly associated with an increase in mortality and a poor prognosis.

CLINICA CHIMICA ACTA (2021)

Add to Collection

Article Immunology

Proinflammatory IgG Fc structures in patients with severe COVID-19

Saborni Chakraborty, Joseph Gonzalez, Karlie Edwards, Vamsee Mallajosyula, Anthony S. Buzzanco, Robert Sherwood, Cindy Buffone, Nimish Kathale, Susan Providenza, Markus M. Xie, Jason R. Andrews, Catherine A. Blish, Upinder Singh, Haley Dugan, Patrick C. Wilson, Tho D. Pham, Scott D. Boyd, Kari C. Nadeau, Benjamin A. Pinsky, Sheng Zhang, Matthew J. Memoli, Jeffery K. Taubenberger, Tasha Morales, Jeffrey M. Schapiro, Gene S. Tan, Prasanna Jagannathan, Taia T. Wang

Summary: COVID-19 is often characterized by a hyperinflammatory syndrome, and disease severity is associated with specific antibody structures that enhance inflammatory responses.

NATURE IMMUNOLOGY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Omicron COVID-19 variant outcomes and vaccination in non-severe and non-critical patients at admission

Hong Zhao, Wenyi Ye, Xia Yu, Yu Shi, Jifang Sheng

Summary: Retrospective data of patients infected with Omicron variant virus in Zhejiang Province from January to 14 May 2022 were analyzed. The study observed that as the number of vaccine doses increased, the frequency of clinical symptoms decreased and the length of hospital stay was significantly shortened. One, two, and three vaccine doses were found to be effective in reducing hospitalization and the persistence of the virus in the sputum. Therefore, vaccination was concluded to be an effective way to protect against Omicron variant and three doses were necessary.

FRONTIERS IN PUBLIC HEALTH (2023)

Add to Collection

Article Biochemistry & Molecular Biology

The rs16969968 Tobacco Smoking-Related Single-Nucleotide Variant Is Associated with Clinical Markers in Patients with Severe COVID-19

Daniela Valencia-Perez Rea, Ramces Falfan-Valencia, Ingrid Fricke-Galindo, Ivette Buendia-Roldan, Leslie Chavez-Galan, Karol J. Nava-Quiroz, Jesus Alanis-Ponce, Gloria Perez-Rubio

Summary: Tobacco smoking is the leading risk factor for respiratory diseases, and genes like CHRNA5 and ADAM33 are associated with nicotine addiction. This research aimed to evaluate the association of polymorphisms in rs16969968 (CHRNA5) and rs3918396 (ADAM33) with severe COVID-19. The study found a significant correlation between the GA + AA genotype of rs16969968 and higher erythrocyte sedimentation rate (ESR), as well as a positive correlation between fibrinogen and C-reactive protein.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Genetics & Heredity

Single-nucleus transcriptome analysis of human brain immune response in patients with severe COVID-19

John F. Fullard, Hao-Chih Lee, Georgios Voloudakis, Shengbao Suo, Behnam Javidfar, Zhiping Shao, Cyril Peter, Wen Zhang, Shan Jiang, Andre Corvelo, Heather Wargnier, Emma Woodoff-Leith, Dushyant P. Purohit, Sadhna Ahuja, Nadejda M. Tsankova, Nathalie Jette, Gabriel E. Hoffman, Schahram Akbarian, Mary Fowkes, John F. Crary, Guo-Cheng Yuan, Panos Roussos

Summary: Despite the absence of detectable SARS-CoV-2 in the brain at the time of death, the findings suggest significant and persistent neuroinflammation in patients with acute COVID-19. Single-cell transcriptomics studies revealed transcriptional changes in various cell types in specific brain regions of COVID-19 patients, including cellular activation, mobility, and phagocytosis.

GENOME MEDICINE (2021)

Add to Collection

Article Health Care Sciences & Services

Early Response of CD8+ T Cells in COVID-19 Patients

Deni Ramljak, Martina Vukoja, Marina Curlin, Katarina Vukojevic, Maja Barbaric, Una Glamoclija, Bejana Purisevic, Olivera Peric, Violeta Soljic

Summary: The study suggests that CD8+ T cells with higher perforin-1 and lower Fas ligand expression in the early stages of COVID-19 infection may be associated with progression to moderate and severe forms of the disease later on. Additionally, the frequency of effector memory CD8+ T cells was lower in all COVID-19 patients, and the mRNA expression of perforin-1 and interferon-gamma were significantly downregulated.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection

Article Immunology

Repurposed Tocilizumab in Patients with Severe COVID-19

Jianbo Tian, Ming Zhang, Meng Jin, Fengqin Zhang, Qian Chu, Xiaoyang Wang, Can Chen, Huihui Yue, Li Zhang, Ronghui Du, Dong Zhao, Zhaofu Zeng, Yang Zhao, Kui Liu, Mengmei Wang, Ke Hu, Xiaoping Miao, Huilan Zhang

Summary: This study found that tocilizumab treatment in COVID-19 patients can lower the risk of in-hospital death and acute respiratory distress syndrome. Patients had heightened inflammation and dysregulated immune cells before treatment, but these indicators improved after tocilizumab administration.

JOURNAL OF IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19

Xavier Solanich, Gardenia Vargas-Parra, Caspar I. van der Made, Annet Simons, Janneke Schuurs-Hoeijmakers, Arnau Antoli, Jesus del Valle, Gemma Rocamora-Blanch, Fernando Setien, Manel Esteller, Simon V. van Reijmersdal, Antoni Riera-Mestre, Joan Sabater-Riera, Gabriel Capella, Frank L. van de Veerdonk, Ben van der Hoven, Xavier Corbella, Alexander Hoischen, Conxi Lazaro

Summary: The study found loss-of-function TLR7 variants in young men with severe COVID-19, which may result in weakened interferon responses to the virus. Additionally, siblings of two patients carrying the variants also showed different degrees of disease symptoms, indicating a potential genetic predisposition.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Severe COVID-19 and non-COVID-19 severe sepsis converge transcriptionally after a week in the intensive care unit, indicating common disease mechanisms

Andy Y. An, Arjun Baghela, Peter Zhang, Reza Falsafi, Amy H. Lee, Uriel Trahtemberg, Andrew J. Baker, Claudia C. dos Santos, Robert E. W. Hancock

Summary: This study compared the gene expression trajectories between severe COVID-19 patients and contemporaneous non-COVID-19 severe sepsis patients during hospitalization. COVID-19 patients had 1,215 differentially expressed genes compared to non-COVID-19 sepsis patients at ICU admission, but the number dropped to 9 genes after one week. The findings highlight the importance of early antiviral treatment for COVID-19 and the potential for heme-related therapeutics.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Genetics & Heredity

Protective Role of a TMPRSS2 Variant on Severe COVID-19 Outcome in Young Males and Elderly Women

Maria Monticelli, Bruno Hay Mele, Elisa Benetti, Chiara Fallerini, Margherita Baldassarri, Simone Furini, Elisa Frullanti, Francesca Mari, Giuseppina Andreotti, Maria Vittoria Cubellis, Alessandra Renieri

Summary: The study analyzed the sequence of the TMPRSS2 gene and identified common variants with potentially deleterious effects on the protease activity, particularly p.V197M (p.Val197Met), which showed a protective effect on COVID-19 patients, especially in young males, elderly women, and those with co-morbidities.

GENES (2021)

Add to Collection

Article Cell Biology

COVID-19: risk factors for severe cases of the Delta variant

Kaiyuan Hu, Liu Lin, Ying Liang, Xinning Shao, Zhongwei Hu, Hongbin Luo, Ming Lei

Summary: The study found that older age and elevated total bilirubin were independent risk factors for severe cases of the Delta variant in Guangzhou, especially if the age was greater than 58.5 years or the total bilirubin level was greater than 7.23 μmol/L.

AGING-US (2021)

Add to Collection

Article Multidisciplinary Sciences

Efficacy and tolerability of bevacizumab in patients with severe Covid-19

Jiaojiao Pang, Feng Xu, Gianmarco Aondio, Yu Li, Alberto Fumagalli, Ming Lu, Giuseppe Valmadre, Jie Wei, Yuan Bian, Margherita Canesi, Giovanni Damiani, Yuan Zhang, Dexin Yu, Jun Chen, Xiang Ji, Wenhai Sui, Bailu Wang, Shuo Wu, Attila Kovacs, Miriam Revera, Hao Wang, Xu Jing, Ying Zhang, Yuguo Chen, Yihai Cao

Summary: In this single-arm clinical trial, the authors show that treatment of COVID-19 patients with bevacizumab, an anti-vascular endothelial growth factor drug, can improve PaO2/FiO(2) ratios and oxygen-support status. Relative to an external control group, bevacizumab shows clinical efficacy by improving oxygenation.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Immunology

Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency

Daniel Arroyo-Sanchez, Oscar Cabrera-Marante, Rocio Laguna-Goya, Patricia Almendro-Vazquez, Octavio Carretero, Francisco Javier Gil-Etayo, Patricia Suarez-Fernandez, Pilar Perez-Romero, Edgard Rodriguez de Frias, Antonio Serrano, Luis M. Allende, Daniel Pleguezuelo, Estela Paz-Artal

Summary: Common Variable Immunodeficiency (CVID) patients show slower humoral and cellular responses to COVID-19 vaccination compared to healthy controls. Despite most CVID patients developing S1-specific antibodies and T cells after vaccination, neutralizing antibodies were only detected in half of the patients. Those with absent or discordant responses often had a history of autoimmunity or lymphoproliferation, while recent anti-B cell antibody therapy may also weaken the response. Further studies are necessary to assess the protective efficacy of COVID-19 vaccination in CVID patients, with consideration for a third dose to achieve full immune response.

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer

Antonio Tapia-Galisteo, Inigo Sanchez Rodriguez, Oscar Aguilar-Sopena, Seandean Lykke Harwood, Javier Narbona, Mariola Ferreras Gutierrez, Rocio Navarro, Laura Martin-Garcia, Cesareo Corbacho, Marta Compte, Javier Lacadena, Francisco J. Blanco, Patrick Chames, Pedro Roda-Navarro, Luis Alvarez-Vallina, Laura Sanz

Summary: In this study, a novel trispecific T-cell recruiting antibody was developed for the treatment of colorectal cancer, which showed improved efficacy and enhanced tumor selectivity.

ONCOIMMUNOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

An Early Th1 Response Is a Key Factor for a Favorable COVID-19 Evolution

Francisco Javier Gil-Etayo, Sara Garcinuno, Alberto Utrero-Rico, Oscar Cabrera-Marante, Daniel Arroyo-Sanchez, Esther Mancebo, Daniel Enrique Pleguezuelo, Edgard Rodriguez-Frias, Luis M. Allende, Pablo Morales-Perez, Maria Jose Castro-Panete, Antonio Lalueza, Carlos Lumbreras, Estela Paz-Artal, Antonio Serrano

Summary: The Th1/Th2 balance plays a crucial role in the progression and evolution of infectious diseases. The immune response and T-helper subsets in COVID-19 patients are closely related to the severity of the disease. Asymptomatic individuals show a strong Th1 immune response, while severe patients have a Th17-skewed immune response.

BIOMEDICINES (2022)

Add to Collection

Article Oncology

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers

Belen Blanco, Angel Ramirez-Fernandez, Clara Bueno, Lidia Argemi-Muntadas, Patricia Fuentes, Oscar Aguilar-Sopena, Francisco Gutierrez-Aguera, Samanta Romina Zanetti, Antonio Tapia-Galisteo, Laura Diez-Alonso, Alejandro Segura-Tudela, Maria Castella, Berta Marzal, Sergi Betriu, Seandean L. Harwood, Marta Compte, Simon Lykkemark, Ainhoa Erce-Llamazares, Laura Rubio-Perez, Anais Jimenez-Reinoso, Carmen Dominguez-Alonso, Maria Neves, Pablo Morales, Estela Paz-Artal, Sonia Guedan, Laura Sanz, Maria L. Toribio, Pedro Roda-Navarro, Manel Juan, Pablo Menendez, Luis Alvarez-Vallina

Summary: This study compares the efficacy of CAR-T19 cells and STAb-T19 cells and finds that STAb-T19 cells are more effective in inducing cytotoxicity, avoiding leukemia escape, and preventing relapse. CAR-T19 cells induce leukemia escape through rapid CD19 internalization and degradation, while STAb-T19 cells prevent CD19 downmodulation by forming canonical immunologic synapses. In a long-term patient-derived xenograft mouse model, STAb-T19 cells efficiently eradicate leukemia cells, while leukemia relapse occurs after CAR-T19 therapy.

CANCER IMMUNOLOGY RESEARCH (2022)

Add to Collection

Article Oncology

Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies

Angel Ramirez-Fernandez, Oscar Aguilar-Sopena, Laura Diez-Alonso, Alejandro Segura-Tudela, Carmen Dominguez-Alonso, Pedro Roda-Navarro, Luis alvarez-Vallina, Belen Blanco

Summary: Cancer immunotherapy strategies based on STAb-T cells may be more effective and safer than CAR-T approaches, as STAb-T cells form artificial immunological synapses that closely resemble physiological synapses and do not cause acute loss of CD19 in target cells.

ONCOIMMUNOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity

Oana Hangiu, Marta Compte, Anders Dinesen, Rocio Navarro, Antonio Tapia-Galisteo, Ole A. Mandrup, Ainhoa Erce-Llamazares, Rodrigo Lazaro-Gorines, Daniel Nehme-Alvarez, Carmen Dominguez-Alonso, Seandean L. Harwood, Carlos Alfonso, Belen Blanco, Laura Rubio-Perez, Anais Jimenez-Reinoso, Laura Diez-Alonso, Francisco J. Blanco, Laura Sanz, Kenneth A. Howard, Luis Alvarez-Vallina

Summary: This study introduces bispecific antibodies fused with human and mouse sequences that specifically target the tumor microenvironment to provide 4-1BB costimulation. These antibodies show specific targeting of the tumor cells and provide costimulatory activity, with prolonged circulatory half-life and tumor inhibition effects. Combining these antibodies with PD-1-blocking antibodies enhances the therapeutic effect.

ISCIENCE (2022)

Add to Collection

Article Surgery

First case report of multivisceral transplant from a deceased cardiac death donor

Ane M. Andres, Jose Luis Encinas, Alba Sanchez-Galan, Javier Serradilla Rodriguez, Karla Estefania, Rocio Gonzalez Sacristan, Alida Alcolea, Pilar Serrano, Belen Estebanez, Inigo Velasco Leon, Paula Burgos, Alvaro Gonzalez Rocafort, Bunty Ramchandani, Belen Calderon, Cristina Verdu, Esperanza Jimenez, Paloma Talayero, Pablo Stringa, Itziar de la Pena Navarro, Esther Ramos, Francisco Hernandez Oliveros

Summary: The shortage of pediatric multivisceral donors leads to long waiting times and high mortality rates for pediatric patients. The use of donors after cardiac death, particularly with normothermic regional perfusion, has increased for solid organ transplantation, except for the intestine. This case demonstrates the possibility of reducing waiting time for patients through multivisceral transplantation from donors after cardiac death.

AMERICAN JOURNAL OF TRANSPLANTATION (2023)

Add to Collection

Article Immunology

COVID-19 and the antiphospholipid syndrome

Manuel Serrano, Gerard Espinosa, Antonio Serrano, Ricard Cervera

Summary: COVID-19 not only affects the respiratory system, but also has an impact on the cardiovascular system, causing coagulation abnormalities and potentially increasing the risk of thrombotic events and mortality. This multiorgan vascular disease overlaps with other known microangiopathies and may be associated with inflammatory response and coagulopathy.

AUTOIMMUNITY REVIEWS (2022)

Add to Collection

Review Medicine, Research & Experimental

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy

Antonio Tapia-Galisteo, Marta Compte, Luis alvarez-Vallina, Laura Sanz

Summary: Multispecific antibodies have the potential to overcome current limitations and have important implications in cancer therapy.

THERANOSTICS (2023)

Add to Collection

Article Pediatrics

Antibody-removal therapies for de novo DSA in pediatric intestinal recipients: Why, when, and how? A single-center experience

Maria Lasa-Lazaro, Esther Ramos-Boluda, Esther Mancebo, Maria Jose Castro-Panete, Rocio Gonzalez-Sacristan, Javier Serradilla, Ane Miren Andres-Moreno, Francisco Hernandez-Oliveros, Estela Paz-Artal, Paloma Talayero

Summary: This study demonstrates the effectiveness of antibody-removal therapies (ART) in pediatric intestinal and multivisceral transplants with de novo donor-specific anti-HLA antibodies (dnDSA). ART was successful in removing DSA and preventing rejection even in the absence of clinical symptoms.

FRONTIERS IN PEDIATRICS (2023)

Add to Collection

Article Oncology

Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers

Anais Jimenez-Reinoso, Nestor Tirado, Alba Martinez-Moreno, Victor M. Diaz, Marina Garcia-Peydro, Oana Hangiu, Laura Diez-Alonso, Angela Albitre, Petronila Penela, Maria L. Toribio, Pablo Menendez, Luis Alvarez-Vallina, Diego Sanchez Martinez

Summary: CD1a-STAb T cells could be an alternative to CD1a-CAR T cells for coT-ALL patients with aggressive and hyperleukocytic relapses and limited numbers of non-leukemic effector T cells.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Medicine, Research & Experimental

10th antibody industrial symposium: new developments in antibody and adoptive cell therapies

Ana Antunes, Luis Alvarez-Vallina, Federico Bertoglio, Nicolas Bouquin, Stephanie Cornen, Francis Duffieux, Pierre Ferre, Raphaelle Gillet, Christian Jorgensen, Mark B. Leick, Bernard Maillere, Helene Negre, Mireia Pelegrin, Nicolas Poirier, Dietmar Reusch, Bruno Robert, Guy Serre, Alain Vicari, Martin Villalba, Christoph Volpers, Gavin Vuddamalay, Herve Watier, Thierry Wurch, Lennart Zabeau, Stefan Zielonka, Baolin Zhang, Alain Beck, Pierre Martineau

Summary: The annual Antibody Industrial Symposium brought together scientists from academia and industry to discuss new advancements in antibody engineering and cell-based therapies. The symposium also addressed production and intellectual property protection issues.

MABS (2023)

Add to Collection

Article Oncology

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

Laura Rubio-Perez, Rodrigo Lazaro-Gorines, Seandean L. Harwood, Marta Compte, Rocio Navarro, Antonio Tapia-Galisteo, Jaume Bonet, Belen Blanco, Simon Lykkemark, Angel Ramirez-Fernandez, Mariola Ferreras-Gutierrez, Carmen Dominguez-Alonso, Laura Diez-Alonso, Alejandro Segura-Tudela, Oana Hangiu, Ainhoa Erce-Llamazares, Francisco J. Blanco, Cruz Santos, Jose L. Rodriguez-Peralto, Laura Sanz, Luis Alvarez-Vallina

Summary: In this study, a PD-L1/EGFR symmetric bispecific antibody was developed, which could simultaneously inhibit EGFR-mediated proliferation, effectively block PD-1/PD-L1 interaction, and induce strong antigen-specific antibody-dependent cellular cytotoxicity activity in vitro. Potent therapeutic efficacies of this antibody were observed in two different humanized mouse models.

ONCOIMMUNOLOGY (2023)

Add to Collection

Review Oncology

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies

Antonio Tapia-Galisteo, Luis alvarez-Vallina, Laura Sanz

Summary: Immune cell engagers are modified antibodies that have one arm binding a tumor-associated antigen and another arm binding an activating receptor in immune effector cells. These engagers have the potential to revolutionize the treatment of hematological malignancies and are more potent than conventional monoclonal antibodies. The field is growing rapidly, with multiple formats and targets currently in clinical trials, and trispecific antibodies show even more promise by targeting additional tumor-associated antigens or costimulatory receptors.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Add to Collection

Article Respiratory System

Derivation and external validation of a simple prediction rule for the development of respiratory failure in hospitalized patients with influenza

Blanca Ayuso, Antonio Lalueza, Estibaliz Arrieta, Eva Maria Romay, Alvaro Marchan-Lopez, Maria Jose Garcia-Pais, Dolores Folgueira, Maria Jose Gude, Cecilia Cueto, Antonio Serrano, Carlos Lumbreras

Summary: A simple and well-calibrated clinical prediction rule for early prediction of respiratory failure in hospitalized Influenza patients was developed. This tool may be helpful in patient stratification during seasonal Influenza epidemics.

RESPIRATORY RESEARCH (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.